Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
AGUERIN B
ID: ALA520721
Max Phase: Preclinical
Molecular Formula: C19H22O5
Molecular Weight: 330.38
Molecule Type: Small molecule
Associated Items:
ID: ALA520721
Max Phase: Preclinical
Molecular Formula: C19H22O5
Molecular Weight: 330.38
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: C=C(C)C(=O)O[C@H]1CC(=C)[C@@H]2C[C@H](O)C(=C)[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]21
Standard InChI: InChI=1S/C19H22O5/c1-8(2)18(21)23-14-6-9(3)12-7-13(20)10(4)15(12)17-16(14)11(5)19(22)24-17/h12-17,20H,1,3-7H2,2H3/t12-,13-,14-,15-,16+,17+/m0/s1
Standard InChI Key: ZGDWDAMVZDRRQA-NQLMQOPMSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: Yes | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 330.38 | Molecular Weight (Monoisotopic): 330.1467 | AlogP: 2.09 | #Rotatable Bonds: 2 |
Polar Surface Area: 72.83 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: | CX LogP: 2.33 | CX LogD: 2.33 |
Aromatic Rings: 0 | Heavy Atoms: 24 | QED Weighted: 0.48 | Np Likeness Score: 3.39 |
1. Bruno M, Rosselli S, Maggio A, Raccuglia RA, Bastow KF, Lee KH.. (2005) Cytotoxic activity of some natural and synthetic guaianolides., 68 (7): [PMID:16038545] [10.1021/np0500575] |
2. Chicca A, Tebano M, Adinolfi B, Ertugrul K, Flamini G, Nieri P.. (2011) Anti-proliferative activity of aguerin B and a new rare nor-guaianolide lactone isolated from the aerial parts of Centaurea deflexa., 46 (7): [PMID:21458113] [10.1016/j.ejmech.2011.03.011] |
3. Cis J, Nowak G, Kisiel W. (2006) Antifeedant properties and chemotaxonomic implications of sesquiterpene lactones and syringin from Rhaponticum pulchrum, 34 (12): [10.1016/j.bse.2006.05.019] |
4. Usuki T, Sato M, Hara S, Yoshimoto Y, Kondo R, Zimmermann S, Kaiser M, Brun R, Hamburger M, Adams M.. (2014) Antitrypanosomal structure-activity-relationship study of synthetic cynaropicrin derivatives., 24 (3): [PMID:24433861] [10.1016/j.bmcl.2013.12.099] |
Source(1):